Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Patient safety

Trials of genetic heart failure drug halted after patient deaths

John Maraganore, chief executive officer at Alnylam Pharmaceuticals

Source: Alnylam Pharmaceuticals

John Maraganore, chief executive officer at Alnylam Pharmaceuticals, says the company has stopped all dosing and is monitoring patients across revusiran studies to ensure their safety

Alnylam Pharmaceuticals has discontinued development of an experimental therapy for a rare genetic condition that can cause heart failure because of higher death rates in patients taking the drug in late stage trials.

Revusiran, an investigational RNA interference (RNAi) therapeutic, was being developed to treat hereditary amyloidosis with cardiomyopathy, a condition in which amyloid plaque — similar to the substance found in the brains of Alzheimers’ patients — collects in organs including the heart, where it can cause heart failure.

Following recent reports of new onset or worsening peripheral neuropathy with revusiran in the phase II open-label study, the company asked the ENDEAVOUR Data Monitoring Committee (DMC) to review the data on an unblinded basis. The DMC did not find conclusive evidence for drug-related neuropathy, but informed the company that the benefit-risk profile for revusiran no longer supported continued dosing. A subsequent review of the unblinded ENDEAVOUR data by Alnylam Pharmaceuticals revealed higher rates of mortality in the revusiran arm than the placebo.

John Maraganore, chief executive officer at Alnylam, says: “Patient safety comes first. We have stopped all dosing and are actively monitoring patients across revusiran studies to ensure their safety. We will also continue to evaluate ENDEAVOUR data to understand the potential cause of these findings.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201803

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • John Maraganore, chief executive officer at Alnylam Pharmaceuticals

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.